Status: Recommended | ||
Clostridium botulinum neurotoxin type A (Xeomin®) is recommended as an option for use within NHS Wales for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhoea due to neurological/neurodevelopmental disorders. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
||
|
||
Medicine details |
||
Medicine name | clostridium botulinum neurotoxin type A (Xeomin®) | |
Formulation | 50 units powder for solution for injection, 100 units powder for solution for injection, 200 units powder for solution for injection | |
Reference number | 3986 | |
Indication | Symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhoea due to neurological/neurodevelopmental disorders |
|
Company | Merz Pharma UK Ltd | |
BNF chapter | Central nervous system | |
Submission type | Licence extension for paediatric use | |
Status | Recommended | |
Advice number | 2021 | |
AWMSG meeting date | 08/12/2021 | |
Date of issue | 10/12/2021 | |
Commercial arrangement | PAS | |
Further information See also TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (in adults) |